Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430

Oncologist

Volumn 17, Issue 2, 2012, Pages 179-187

  Schott, Anne F ^a   Barlow, William E ^b   Albain, Kathy S ^c   Chew, Helen K ^d   L Wade III, James ^e   Lanier, Keith S ^f   Lew, Danika L ^a   Hayes, Daniel F ^g   Gralow, Julie R ^h   Livingston, Robert B ⁱ   Hortobagyi, Gabriel N ^j  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Oncology Program/Cancer Care   (United States)

^f SWOG Statistical Center ^*  (United States)

^g SWOG STATISTICAL CENTER   (United States)

^h SEATTLE CANCER CARE ALLIANCE   (United States)

ⁱ UNIVERSITY OF ARIZONA   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Metastatic breast cancer capecitabine cyclophosphamide oral therapy

Indexed keywords

CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CAPECITABINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; EVENING DOSAGE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; RASH; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; MUCIN-1; PROSPECTIVE STUDIES;

EID: 84857438768     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0235     Document Type: Article

References (35)

1. Gornas M, Szczylik C. Oral treatment of metastatic breast cancer with capecitabine: What influences the decision-making process? Eur J Cancer Care 2010;19:131-136.
2. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.
3. Pfeiffer P, Mortensen JP, Bjerregaard B et al. Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 2006; 42:2738-2743.
4. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
5. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/ taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-1019.
6. Toi M, Bando H, Horiguchi S et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 2004;90:2338-2343.
7. Endo M, Shinbori N, Fukase Y et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 1999;83: 127-134.
8. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-6943.
9. Tonini G, Schiavon G, Silletta M et al. Antiangiogenic properties of metronomic chemotherapy in breast cancer. Future Oncol 2007;3:183-190.
10. Hainsworth JD, Burris HA 3rd, Erland JB et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-2168.
11. Hainsworth JD, Burris HA 3rd, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001;19:3500-3505.
12. Bocci G, Tuccori M, Emmenegger U, et al. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 2005;16:1243-1252.
13. Smith DC, Dunn RL, Strawderman MS et al. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998;16:1835-1843.
14. Scher HI, Kelly WM, Zhang ZF et al. Posttherapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 1999;91:244-251.
15. Rustin GJ, Nelstrop AE, Bentzen SM, et al. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 2000;18:1733-1739.
16. Abramson V, Mayer I. Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer. Curr Treat Options Oncol 2011;12:403-411.
17. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000;26:91-102.
18. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312.
19. Kurebayashi J, Yamamoto Y, Tanaka K et al. Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: A largescale retrospective study. Breast Cancer 2003;10: 38-44.
20. Sonoo H, Kurebayashi J. Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Surgery Today 1996;26: 250-257.
21. Yasasever V, Dinȩr M, Camlica H et al. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: Special emphasis on "spiking" phenomena. Clin Biochem 1997;30:53-56.
22. Kim HS, Park YH, Park MJ et al. Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat 2009;118: 89-97.
23. Tyshler LB, Longton GM, Ellis GK et al. False positive tumor markers: Elevation in patients with breast cancer on FAC-type chemotherapy and correlation with the development of hand-foot syndrome. Int J Biol Markers 1996;11:203-206.
24. Cassidy J, Twelves C, Cameron D et al. Bioequivalence to two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999;44:453-460.
25. Baker SD, Verweij J, Rowinsky EK et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94:1883-1888.
26. Tominaga T, Koyama H, Toge T et al. Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. J Clin Oncol 2003;21: 991-998.
27. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxanepretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-1768.
28. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxelrefractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
29. Fumoleau P, Largillier R, Clippe C et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40:536-542.
30. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-1233.
31. Tanaka M, Takamatsu Y, Anan K et al. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study. Anticancer drugs 2010;21:453-458.
32. Robert N, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with our without bevacizumab (B) for first-line treatment of Her-2 negative locally recurrent or metastatic breast cancer (MBC). Presented at the 2009 American Society of Clinical Oncology Annual Meeting, Orlando, FL, June 1, 2009.
33. Brufsky A et al. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of Her-2 negative metastatic breast cancer. Presented at the 2009 Cancer Therapy & Research Center-American Association for Cancer Research San Antonio Breast Cancer Symposium, San Antonio, TX, December 11, 2009.
34. Baselga J et al. SOLTI-071: A multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Presented at the 2009 Cancer Therapy & Research Center-American Association for Cancer Research San Antonio Breast Cancer Symposium, San Antonio, TX, December 11, 2009.
35. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-5217.